Back

Quick and sustained right ventricular reverse remodeling at early, mid and late follow-Up under sotatercept

30 August 2026 (17:24 - 17:36)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of pulmonary arterial hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Manel EL BLIDI

Hospital Kremlin Bicetre, Le Kremlin-Bicetre (France)

4 More presentations in this session

Presentation thumbnail
Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial
Doctor M. Ersboll (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of treprostinil in pulmonary arterial hypertension: a meta-analysis of randomized trials
Doctor M. Malik (Lahore, Punjab, PK)
Abstract Slides Video
Presentation thumbnail
Impact of targeted therapies withPDE5 inhibitors, endothelin receptor antagonists and sotatercept on functional tricuspid regurgitation in pulmonary arterial hypertension
Mr J. Gentz (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Early therapy failure in incident pulmonary arterial hypertension
Doctor G. Savonitto (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy of pulmonary arterial hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 17:24 CET
You may be interested in
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
27 August 2023
thumbnail
Congress Presentation
Right ventricular remodelling in pulmonary arterial hypertension after sotatercept therapy
28 August 2026
thumbnail
Congress Presentation
Sotatercept as an alternative therapeutic strategy in high-risk pulmonary hypertension associated with systemic sclerosis and interstitial lung disease when prostacyclin therapy is not feasible
29 August 2026
thumbnail
Congress Presentation
Prognostic Impact and Structural Recovery in HFrEF Patients on Vericiguat with PH and Tricuspid Regurgitation: Results from the VERISEC Registry
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources